1. Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study
- Author
-
York Pei, Steffan F. Stella, Korosh Khalili, Ioan-Andrei Iliuta, Marina Pourafkari, Eran Shlomovitz, Ralph Hsiao, Pedram Akbari, Beili Shi, and Giancarlo Bruni
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030232 urology & nephrology ,Autosomal dominant polycystic kidney disease ,Urology ,Renal function ,Kidney Volume ,030204 cardiovascular system & hematology ,lcsh:RC870-923 ,Kidney cysts ,03 medical and health sciences ,kidney volume reduction ,0302 clinical medicine ,cyst ablation ,Internal Medicine ,Sclerotherapy ,medicine ,Prospective cohort study ,Original Research ,autosomal dominant polycystic kidney disease ,business.industry ,urogenital system ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,3. Good health ,Nephrology ,Renal blood flow ,Kidney disorder ,medicine.symptom ,business ,Foam sclerotherapy - Abstract
Rationale & Objective Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder. Progressive increase in cyst number and size leads to kidney failure in a majority of patients. Large kidney cysts, although few, can be especially deleterious by impeding kidney blood flow and obstructing urine flow over a large region. Foam sclerotherapy is a minimally invasive procedure that may be used to ablate large cysts. We examined the effectiveness and safety of foam sclerotherapy for kidney volume reduction in patients with ADPKD. Study Design Prospective cohort study. Setting & Participants Adults with ADPKD at a tertiary referral center in Toronto. Predictor Foam sclerotherapy. Outcomes Volume of treated kidneys and adverse events. Analytical Approach Treated and nontreated kidney volume, kidney function, tolerability, and symptoms were analyzed within each patient. Results We performed 77 foam sclerotherapy treatment sessions in 66 patients. Foam sclerotherapy was associated with a 21.8% volume reduction of the treated kidneys (n = 95; median, 1,138 [IQR, 801-1,582] mL before vs 891 [IQR, 548-1,450] mL after; P, Graphical abstract
- Published
- 2019